Dengue Fever (Breakbone Fever) (Flavivirus)
Overview
Plain-Language Overview
Dengue Fever (Breakbone Fever) is a viral illness caused by the dengue virus, which is transmitted to humans through the bite of infected Aedes mosquitoes. It primarily affects the blood vessels and the immune system, leading to symptoms such as high fever, severe muscle and joint pain, and a characteristic rash. The disease can cause significant discomfort and weakness, often described as feeling like the bones are breaking. In some cases, it can progress to a more severe form with bleeding and low platelet counts, which can be life-threatening. The illness usually lasts about one to two weeks and mainly impacts people living in or traveling to tropical and subtropical regions.
Clinical Definition
Dengue Fever (Breakbone Fever) is an acute febrile illness caused by infection with one of four serotypes of the dengue virus, a single-stranded RNA virus of the Flavivirus genus. The virus is transmitted by the bite of infected female Aedes aegypti or Aedes albopictus mosquitoes. The core pathology involves viral replication in monocytes and dendritic cells, leading to a systemic inflammatory response and increased vascular permeability. Clinically, it presents with sudden onset of high fever, severe myalgia and arthralgia, headache, retro-orbital pain, and a characteristic maculopapular rash. Severe cases may progress to dengue hemorrhagic fever or dengue shock syndrome, characterized by plasma leakage, bleeding, and organ impairment. The disease is a major cause of morbidity in endemic tropical regions and poses significant public health challenges.
Inciting Event
Bite from an infected female Aedes aegypti or Aedes albopictus mosquito transmits the dengue virus.
Secondary infection with a different dengue virus serotype triggers antibody-dependent enhancement and severe disease.
Exposure to high mosquito density environments during rainy seasons increases infection risk.
Latency Period
The incubation period ranges from 4 to 10 days after the mosquito bite.
Symptoms typically develop within 5 to 7 days post-exposure.
Viremia peaks during the febrile phase, usually within the first 3 to 5 days of illness.
Diagnostic Delay
Early symptoms mimic other febrile illnesses like influenza or malaria, leading to misdiagnosis.
Lack of access to dengue-specific serologic or PCR testing delays confirmation.
Mild cases may not seek medical attention, causing underdiagnosis.
Overlap with other arboviral infections such as Zika or Chikungunya complicates diagnosis.
Clinical Presentation
Signs & Symptoms
Sudden high fever lasting 2-7 days
Severe myalgia and arthralgia causing the name 'breakbone fever'
Retro-orbital headache and intense eye pain
Nausea, vomiting, and abdominal pain
Rash appearing 3-5 days after fever onset, often maculopapular
Bleeding manifestations such as petechiae, gum bleeding, or epistaxis
History of Present Illness
Sudden onset of high fever lasting 2 to 7 days is the hallmark initial symptom.
Severe myalgias and arthralgias cause the characteristic 'breakbone' pain.
Patients often report retro-orbital headache and rash appearing 3 to 5 days after fever onset.
Bleeding manifestations such as petechiae, mucosal bleeding, or epistaxis may develop in severe cases.
Symptoms may progress to plasma leakage syndrome with signs of shock in dengue hemorrhagic fever.
Past Medical History
Previous dengue virus infection increases risk of severe disease due to antibody-dependent enhancement.
History of immunosuppression or chronic illnesses may worsen clinical course.
Prior vaccination with the Dengvaxia vaccine is relevant for risk stratification in endemic areas.
No specific chronic conditions are required for typical dengue fever presentation.
Family History
No known heritable genetic predisposition significantly influences dengue susceptibility or severity.
Familial clustering may occur due to shared environmental exposure to infected mosquitoes.
No familial syndromes are associated with dengue fever.
Physical Exam Findings
High fever often >40°C (104°F) during the febrile phase
Diffuse maculopapular rash appearing after fever onset
Petechiae and mucosal bleeding indicating capillary fragility
Positive tourniquet test showing petechiae after cuff inflation
Hepatomegaly may be present in severe cases
Tachycardia and hypotension in cases progressing to shock
Diagnostic Workup
Diagnostic Criteria
Diagnosis of dengue fever is established by a combination of clinical presentation and laboratory testing. Key diagnostic criteria include acute febrile illness with two or more symptoms such as headache, retro-orbital pain, myalgia, arthralgia, rash, or hemorrhagic manifestations. Laboratory confirmation is achieved by detection of dengue virus RNA by RT-PCR during the early febrile phase or identification of NS1 antigen. Serologic testing for dengue-specific IgM and IgG antibodies can confirm recent or past infection, with IgM appearing after day 5 of illness. Complete blood count often shows leukopenia and thrombocytopenia, supporting the diagnosis.
Pathophysiology
Key Mechanisms
Dengue virus infection causes widespread immune activation leading to a cytokine storm and increased vascular permeability.
Antibody-dependent enhancement (ADE) during secondary infection with a different serotype increases viral entry into monocytes and worsens disease severity.
Capillary leakage results in plasma extravasation, causing hemoconcentration and hypovolemia.
Thrombocytopenia occurs due to bone marrow suppression and immune-mediated platelet destruction.
Coagulopathy arises from consumption of clotting factors and endothelial dysfunction, increasing bleeding risk.
| Involvement | Details |
|---|---|
| Organs | Liver involvement causes mild hepatomegaly and elevated transaminases due to viral cytopathic effects. |
Spleen may be enlarged due to immune activation and clearance of infected cells. | |
Skin manifests petechiae and rash due to capillary fragility and thrombocytopenia. | |
| Tissues | Vascular endothelium is critically involved in increased permeability causing plasma leakage and hemorrhagic manifestations. |
Bone marrow suppression leads to decreased production of platelets and leukocytes during infection. | |
| Cells | Monocytes are primary targets for dengue virus replication and contribute to cytokine release. |
Platelets are decreased due to immune-mediated destruction and bone marrow suppression, leading to bleeding risk. | |
Endothelial cells become activated and dysfunctional, contributing to increased vascular permeability. | |
| Chemical Mediators | Cytokines such as tumor necrosis factor-alpha and interleukins mediate systemic inflammation and vascular leakage. |
Complement system activation contributes to immune complex formation and endothelial damage. | |
NS1 antigen is a viral protein that triggers immune responses and can be detected for early diagnosis. |
Treatments
Pharmacological Treatments
Acetaminophen
- Mechanism:
Inhibits central prostaglandin synthesis to reduce fever and pain.
- Side effects:
Hepatotoxicity with overdose
Rare allergic reactions
- Clinical role:
First-line
Intravenous fluids
- Mechanism:
Restores intravascular volume to prevent shock from plasma leakage.
- Side effects:
Fluid overload
Electrolyte imbalance
- Clinical role:
Supportive
Non-pharmacological Treatments
Strict bed rest to reduce metabolic demand during the febrile phase.
Close monitoring of vital signs and hematocrit to detect early signs of hemorrhage or shock.
Avoidance of nonsteroidal anti-inflammatory drugs and aspirin to prevent bleeding complications.
Prevention
Pharmacological Prevention
Dengvaxia vaccine recommended for individuals with prior dengue infection
No effective antiviral medications currently available for prophylaxis
Supportive care remains the mainstay during outbreaks
Non-pharmacological Prevention
Mosquito control measures including elimination of breeding sites
Use of insect repellents containing DEET or picaridin
Wearing protective clothing to reduce mosquito bites
Community education on vector avoidance and early symptom recognition
Window screens and bed nets to prevent mosquito exposure
Outcome & Complications
Complications
Dengue hemorrhagic fever (DHF) characterized by plasma leakage and bleeding
Dengue shock syndrome (DSS) with circulatory failure and hypotension
Severe bleeding including gastrointestinal hemorrhage
Organ failure such as acute liver failure or myocarditis
Secondary bacterial infections due to immune compromise
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Dengue Fever (Breakbone Fever) (Flavivirus) versus Chikungunya Virus Infection
Dengue Fever (Breakbone Fever) (Flavivirus) | Chikungunya Virus Infection |
|---|---|
Recent travel to tropical regions with endemic Aedes aegypti mosquito exposure | Recent travel to areas with active Aedes mosquito transmission including Africa and Asia |
Severe myalgia and bone pain typically resolving within 1-2 weeks | Severe polyarthralgia and arthritis persisting for weeks to months |
Marked thrombocytopenia and leukopenia common | Normal or mildly decreased platelet count with elevated inflammatory markers |
Positive RT-PCR or IgM serology for dengue virus | Positive RT-PCR or IgM serology for chikungunya virus |
Dengue Fever (Breakbone Fever) (Flavivirus) versus Zika Virus Infection
Dengue Fever (Breakbone Fever) (Flavivirus) | Zika Virus Infection |
|---|---|
Exposure in dengue-endemic tropical regions with Aedes mosquito bites | Exposure in areas with Zika outbreaks, often overlapping with dengue endemic zones |
High fever with severe myalgia and retro-orbital headache | Mild febrile illness with prominent conjunctivitis and rash |
Significant thrombocytopenia common | Mild thrombocytopenia or normal platelet count |
Positive dengue virus RT-PCR or IgM serology | Positive Zika virus RT-PCR or IgM serology |
Dengue Fever (Breakbone Fever) (Flavivirus) versus Malaria
Dengue Fever (Breakbone Fever) (Flavivirus) | Malaria |
|---|---|
Travel to tropical regions with Aedes mosquito exposure | Travel to or residence in malaria-endemic regions with Anopheles mosquito exposure |
Continuous high fever with severe myalgia and rash | Cyclic fevers with chills and sweats, often paroxysmal |
Thrombocytopenia and leukopenia without parasites on smear | Anemia and parasitemia on peripheral blood smear |
Positive dengue virus RT-PCR or NS1 antigen test | Positive blood smear for Plasmodium species |
Dengue Fever (Breakbone Fever) (Flavivirus) versus Leptospirosis
Dengue Fever (Breakbone Fever) (Flavivirus) | Leptospirosis |
|---|---|
Exposure to mosquito bites in tropical urban or peri-urban areas | Exposure to contaminated water or animal urine in endemic areas |
Acute febrile illness with rash and severe bone pain without jaundice | Biphasic illness with initial fever and myalgia followed by jaundice and renal impairment |
Marked thrombocytopenia and leukopenia without significant liver or kidney dysfunction | Elevated bilirubin and creatinine with mild thrombocytopenia |
Positive dengue virus serology or antigen test | Positive microscopic agglutination test or PCR for Leptospira |
Dengue Fever (Breakbone Fever) (Flavivirus) versus Typhoid Fever
Dengue Fever (Breakbone Fever) (Flavivirus) | Typhoid Fever |
|---|---|
Mosquito bite exposure in tropical endemic areas | Ingestion of contaminated food or water in endemic regions |
Sudden onset high fever with severe myalgia and rash | Stepwise fever progression with abdominal pain and constipation or diarrhea |
Leukopenia with thrombocytopenia and positive dengue serology | Leukopenia with relative lymphocytosis and positive blood cultures |
Positive dengue virus RT-PCR or NS1 antigen | Positive blood culture for Salmonella typhi |